Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Dengue Epidemic Is a Global Recurrent Crisis: Review of the Literature

Version 1 : Received: 14 April 2020 / Approved: 15 April 2020 / Online: 15 April 2020 (10:45:10 CEST)
Version 2 : Received: 12 May 2020 / Approved: 14 May 2020 / Online: 14 May 2020 (08:36:39 CEST)

A peer-reviewed article of this Preprint also exists.

Journal reference: Electronic Journal of General Medicine 2021
DOI: 10.29333/ejgm/8948


Purpose: This review highlights the global scenario of dengue outbreaks, dengue pathogenesis, symptoms, immune response, diagnosis methods and preventive measures which facilitates the better understanding of the global expansion and concerns relating to the disease. Recent Findings: A recent study showed that natural killer cells of the infected person become activated soon after the infection which may help in treatment and vaccine development. A research team has also produced synthetically engineered mosquitoes that can prevent the transmission and dissemination of the dengue virus by the activation of an antibody. Furthermore, a mutation in the protein envelope of the dengue virus leads to variation in shapes, developing resistance towards the vaccine. Summary: The mosquito vectors marked their worldwide distribution through an increasing number of reported cases which was further facilitated by the growth in the shipping and commerce industries. The immune system, through activation of the innate and adaptive immune responses, facilitates the recruitment of an array of leukocytes which help neutralize the virus. Apart from the laboratory standard PRNT method, several other dengue detection methods such as ELISA, RT-LAMP and several optical, microfluidic and electrochemical methods have been developed. The existence of the 4 different viral serotypes makes the secondary infection life-threatening and also leads to difficulties in vaccine development. Since Dengvaxia® (CYD-TDV) has its own set of drawbacks and limitations, several companies have been investing for the production of more potential vaccines that are currently in trial.


Dengue Hemorrhagic Fever (DHF); Aedes Aegypti; epidemic; pathogenesis; identification; vaccine

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.